Abstract B047: Predictive Molecular Signatures of Tumor Reactivity from Antigen Specific Tumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC)

Abstract Background Accurate identification of tumor-reactive T cells in the tumor microenvironment (TME) is critical to understand mechanisms of response and resistance to immunotherapy and to engineer effective cellular therapies. In contrast to patient-specific, mutation associated neoantigens (MANA), viral proteins are expressed in all HPV-positive cancers, thus providing a unique opportunity to identify and characterize tumor-reactive T cells across patients. Methods We performed the Functional Expansion of Specific T cell (FEST) assay using 176 CMV-EBV-Flu virus (CEFX) peptides and 587 overlapping 15 amino acid peptide pools representing the entire HPV16 peptidome on 30 newly-diagnosed, HPV16-positive OPC patients before and during induction CTLA-4 and PD-1 immune checkpoint blockade (iICB). In a subset of 19 patients, overlapping peptides for expressed MANA identified by whole exome sequencing and RNASeq of tumor were included in the assay. T cell receptors (TCRs) for antigen-experienced T cells that significantly expand in vitro in peptide vs. no-peptide control were identified by Immunoseq. The antigen-specific TCR clonotypes were used to identify and phenotype tumor-reactive CD8+TILs in the TME in paired tumor biopsy samples (28 patients) with single-cell profiling by scRNA-seq and scTCR-seq on the 10X platform. Results The FEST assay identified a total of 9748 HPV-, 2373 MANA-, and 2639 CEFX-reactive TCRs in the blood of 30 patients. When tracked into the TME, HPV-specific CD8+TILS were more frequent and more clonally expanded when compared to CEFX-and MANA-specific TILs. HPV early proteins, such as oncogenic E5-E7, elicited more specific TILs than late proteins. Compared to “bystander” CEFX-specific CD8+ TIL, gene expression signatures (GES) for a tissue-resident memory (TRM) phenotype, cytotoxicity and immune checkpoint were higher in HPV-specific CD8+ TIL. HPV-specific CD8+ TIL in tumors with a major histological response (≤10% residual tumor viability) to iICB exhibited higher cytotoxic and lower checkpoint phenotypes than nonMHRs. Some HPV16-specific TCRs were validated to be tumor specific (n=40) and capable of killing. A tumor-reactive GES score was then calculated via AUCell software and recursive feature elimination from genes upregulated in validated HPV-specific vs “bystander” CEFX-specific CD8+TILs. The score achieved an area under curve (AUC) at 0.94 in a logistic regression model for tumor-reactive TIL prediction, higher than signatures from other groups. More tumor-reactive TILs were predicted using the score and their proportion was correlated with histological response. Conclusions In HPV16-positive OPC, the phenotype of HPV-specific CD8+TILs is associated with pathological response to iICB. A tumor-reactive GES score in scRNAseq data has high accuracy for identifying of tumor-reactive CD8+TIL, thus facilitating the quantification of in the TME and associations with treatment response. These findings enhance the development of personalized cellular therapies by enabling efficient identification of TILs and TCRs. Citation Format: Xianli Jiang, Khaled Sanber, Nils-Petter Rudqvist, Bo Jiang, Joe Dan D., Keiko Akagi, Weihong Xiao, Kelli N. Smith, Ken Chen, Maura L. Gillison. Predictive Molecular Signatures of Tumor Reactivity from Antigen Specific Tumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl):Abstract nr B047.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2024-10-18
DOI
https://doi.org/10.1158/2326-6074.tumimm24-b047
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract B047: Predictive Molecular Signatures of Tumor Reactivity from Antigen Specific Tumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC)

Weihong Xiao, Diana Dan, Khaled Sanber, Maura L. Gillison et al.
Cancer Immunology Research
Cancer Immunotherapy and Biomarkers
article

Abstract B047: Predictive Molecular Signatures of Tumor Reactivity from Antigen Specific Tumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC)

Weihong Xiao, Diana Dan, Khaled Sanber, Maura L. Gillison, Nils-Petter Rudqvist, Kellie N. Smith, Xianli Jiang, Ken Chen, Bo Jiang, Keiko Akagi
article en

Abstract

Abstract Background Accurate identification of tumor-reactive T cells in the tumor microenvironment (TME) is critical to understand mechanisms of response and resistance to immunotherapy and to engineer effective cellular therapies. In contrast to patient-specific, mutation associated neoantigens (MANA), viral proteins are expressed in all HPV-positive cancers, thus providing a unique opportunity to identify and characterize tumor-reactive T cells across patients. Methods We performed the Functional Expansion of Specific T cell (FEST) assay using 176 CMV-EBV-Flu virus (CEFX) peptides and 587 overlapping 15 amino acid peptide pools representing the entire HPV16 peptidome on 30 newly-diagnosed, HPV16-positive OPC patients before and during induction CTLA-4 and PD-1 immune checkpoint blockade (iICB). In a subset of 19 patients, overlapping peptides for expressed MANA identified by whole exome sequencing and RNASeq of tumor were included in the assay. T cell receptors (TCRs) for antigen-experienced T cells that significantly expand in vitro in peptide vs. no-peptide control were identified by Immunoseq. The antigen-specific TCR clonotypes were used to identify and phenotype tumor-reactive CD8+TILs in the TME in paired tumor biopsy samples (28 patients) with single-cell profiling by scRNA-seq and scTCR-seq on the 10X platform. Results The FEST assay identified a total of 9748 HPV-, 2373 MANA-, and 2639 CEFX-reactive TCRs in the blood of 30 patients. When tracked into the TME, HPV-specific CD8+TILS were more frequent and more clonally expanded when compared to CEFX-and MANA-specific TILs. HPV early proteins, such as oncogenic E5-E7, elicited more specific TILs than late proteins. Compared to “bystander” CEFX-specific CD8+ TIL, gene expression signatures (GES) for a tissue-resident memory (TRM) phenotype, cytotoxicity and immune checkpoint were higher in HPV-specific CD8+ TIL. HPV-specific CD8+ TIL in tumors with a major histological response (≤10% residual tumor viability) to iICB exhibited higher cytotoxic and lower checkpoint phenotypes than nonMHRs. Some HPV16-specific TCRs were validated to be tumor specific (n=40) and capable of killing. A tumor-reactive GES score was then calculated via AUCell software and recursive feature elimination from genes upregulated in validated HPV-specific vs “bystander” CEFX-specific CD8+TILs. The score achieved an area under curve (AUC) at 0.94 in a logistic regression model for tumor-reactive TIL prediction, higher than signatures from other groups. More tumor-reactive TILs were predicted using the score and their proportion was correlated with histological response. Conclusions In HPV16-positive OPC, the phenotype of HPV-specific CD8+TILs is associated with pathological response to iICB. A tumor-reactive GES score in scRNAseq data has high accuracy for identifying of tumor-reactive CD8+TIL, thus facilitating the quantification of in the TME and associations with treatment response. These findings enhance the development of personalized cellular therapies by enabling efficient identification of TILs and TCRs. Citation Format: Xianli Jiang, Khaled Sanber, Nils-Petter Rudqvist, Bo Jiang, Joe Dan D., Keiko Akagi, Weihong Xiao, Kelli N. Smith, Ken Chen, Maura L. Gillison. Predictive Molecular Signatures of Tumor Reactivity from Antigen Specific Tumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl):Abstract nr B047.

Cancer Immunology ResearchVol. 12(10_Supplement)
The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US)
Good health and well-being
Openalex Percentile: Top 68%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.